Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-004881
Filing Date
2025-11-13
Accepted
2025-11-13 09:02:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10760
  Complete submission text file 0000902664-25-004881.txt   12573
Mailing Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 617-867-2800
Adage Capital Management, L.P. (Filed by) CIK: 0001535978 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Subject) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94447 | Film No.: 251475728
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)